Breaking News

Cedarburg Hauser Appoints Process Development Director

By Kristin Brooks | February 11, 2014

Tretyakov to lead process and analytical development groups

Alex Tretyakov, Ph.D. has been appointed director of process development at Cedarburg Hauser Pharmaceuticals (CHP). Dr. Tretyakov will lead the company's process and analytical development groups, and will join chief scientific officer John Lynch, in providing technical insight into customer projects.
Most recently, Dr. Tretyakov served as vice president of R&D at PCI Synthesis and Cambridge Major Laboratories.
"In his 25-plus years of industry experience Alex has demonstrated a real ability to streamline processes and drive growth via scientific excellence," said CHP chief executive officer Tony Laughrey. "We are counting on Dr. Tretyakov to help accelerate Cedarburg Hauser's growth and are excited to have him on board."

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks